Beijing, China, December 10, 2025 — Gan & Lee Pharmaceuticals. (hereinafter "Gan & Lee" stock code: 603087.SH) welcomed Letícia Frazão Leme, Minister Counsellor of the Embassy of Brazil in China, and Helena Melchionna, Head of Healthcare、Education and Social Affairs of the Embassy, to its Beijing headquarters. The visit focused on Gan & Lee's business expansion in Brazil, progress on the Parcerias para o Desenvolvimento Produtivo (PDP) project, and future collaboration opportunities for innovative drugs including GZR4 and Bofanglutide injection (development code: GZR18). Both parties engaged in in-depth discussions on exploring new pathways for China – Brazil cooperation in diabetes treatment and public health.

They centered its visit on the innovation capabilities and large-scale manufacturing of Gan & Lee, a leader in China's endocrine and metabolic industry with a strong global presence. They toured Gan & Lee's production facilities and R&D center, gaining a comprehensive understanding of its integrated "R&D – production – sales" system, core competitiveness, and global R&D strategy. Minister Counsellor Letícia Frazão Leme highly praised the company's clinical need-driven innovation and its international-standard quality management system.

During the roundtable, Mr. Kai Du, Executive Vice President and Chief Commercial Officer of Gan & Lee, reviewed Gan & Lee's strategic positioning and achievements in the Brazilian market. He emphasized Gan & Lee's ongoing commitment to providing high-quality treatment options for local patients and supporting Brazil's diabetes prevention and healthcare management. Minister Counsellor Letícia Frazão Leme commended Gan & Lee's long-term contributions in Brazil and reaffirmed the Brazilian Embassy's continued support for expanding bilateral health cooperation. She highlighted that both countries would work together to broaden their collaboration in diabetes treatment and public health.

The visit of the Brazilian diplomatic mission represents high recognition of the fruitful collaboration between Gan & Lee and Brazil and lays a strong foundation for further deepening cooperation. Gan & Lee will continue to drive innovation, expand its global R&D and production network, and accelerate the implementation of the PDP program. The company is committed to providing high-quality diabetes treatments and solutions to support Brazil's chronic disease management and improve its public health system.

Gan & Lee will actively engage in China – Brazil health cooperation with an open, win-win approach to explore further opportunities for joint development, with the ultimate goal of enhancing the health and well-being of people in both countries and advancing global diabetes care.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.